SynthesisFrontiers in immunology2022

Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic Reviews.

Shun-Long Ou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.